88%
IsItCap Score
Truth Potential MeterVery Credible
Very Credible
The Washington Post
FDA gives full approval to first drug to clearly, but modestly, slow Alzheimer's
The FDA granted full approval to Leqembi (lecanemab), a drug that slows cognitive decline in early Alzheimer's disease by 27% over 18 months compared to placebo. The drug removes amyloid beta plaques from the brain.
FDA
FDA approves treatment for adults with Alzheimer's disease
The FDA approved Kisunla (donanemab-azbt) for treatment of Alzheimer's disease in patients with mild cognitive impairment or mild dementia. Clinical trials showed statistically significant reduction in clinical decline compared to placebo.
Baystate Health
New Alzheimer's Disease Drugs Receive FDA Approval, Offering Hope
Three new Alzheimer's drugs have received FDA approval, with lecanemab and donanemab specifically targeting disease progression by clearing amyloid-beta plaques. These represent the first medications to slow disease progression rather than just manage symptoms.
ABC News
New data shows Alzheimer's drug can slow cognitive decline
While confirming the 27% slowing of cognitive decline, the article emphasizes the modest nature of the benefit and notes that longer trials are needed to fully determine efficacy and safety. The drug only applies to early-stage patients.
Get an in-depth analysis of content accuracy, source credibility, potential biases, contextual factors, claim origins, and hidden perspectives.
Create a free account to unlock premium features.
We collect sources that support and challenge the claim, then summarize the strongest points from each side. Here’s what we look for:
Each report combines three independent graders and a source-based rubric to produce a clear, repeatable credibility score:
Each factor contributes to the final credibility score through a weighted algorithm that prioritizes factual accuracy and source reliability while considering contextual factors and potential biases.
We trace the claim's origins and examine the broader context in which it emerged.
Our analysis uncovers less obvious perspectives and potential interpretations.
We identify and analyze potential biases in source materials and narratives.
While our analysis strives for maximum accuracy, we recommend using this report as part of a broader fact-checking toolkit.